

Judit OvÄdi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4033535/publications.pdf>

Version: 2024-02-01

33
papers

1,654
citations

430442

18
h-index

414034

32
g-index

33
all docs

33
docs citations

33
times ranked

2166
citing authors

#	ARTICLE	IF	CITATIONS
1	Challenges in Discovering Drugs That Target the Protein-Protein Interactions of Disordered Proteins. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1550.	1.8	16
2	Co-Transmission of Alpha-Synuclein and TPPP/p25 Inhibits Their Proteolytic Degradation in Human Cell Models. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 666026.	1.6	9
3	Role of Multifunctional Cytoskeletal Filaments in Coronaviridae Infections: Therapeutic Opportunities for COVID-19 in a Nutshell. <i>Cells</i> , 2021, 10, 1818.	1.8	3
4	Anti-Aggregative Effect of the Antioxidant DJ-1 on the TPPP/p25-Derived Pathological Associations of Alpha-Synuclein. <i>Cells</i> , 2021, 10, 2909.	1.8	1
5	Microtubule-Associated Proteins with Regulatory Functions by Day and Pathological Potency at Night. <i>Cells</i> , 2020, 9, 357.	1.8	23
6	Pharmacological targeting of α -synuclein and TPPP/p25 in Parkinson's disease: challenges and opportunities in a Nutshell. <i>FEBS Letters</i> , 2019, 593, 1641-1653.	1.3	11
7	Localization of the zinc binding tubulin polymerization promoting protein in the mice and human eye. <i>Journal of Trace Elements in Medicine and Biology</i> , 2018, 49, 222-230.	1.5	4
8	Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals). <i>Journal of Medicinal Chemistry</i> , 2018, 61, 482-491.	2.9	204
9	Role of the microtubule-associated TPPP/p25 in Parkinson's and related diseases and its therapeutic potential. <i>Expert Review of Proteomics</i> , 2017, 14, 301-309.	1.3	18
10	Challenging drug target for Parkinson's disease: Pathological complex of the chameleon TPPP/p25 and alpha-synuclein proteins. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017, 1863, 310-323.	1.8	23
11	Modulation Of Microtubule Acetylation By The Interplay Of TPPP/p25, SIRT2 And New Anticancer Agents With Anti-SIRT2 Potency. <i>Scientific Reports</i> , 2017, 7, 17070.	1.6	17
12	Selective Sirt2 inhibition by ligand-induced rearrangement of the active site. <i>Nature Communications</i> , 2015, 6, 6263.	5.8	222
13	Targeting the interface of the pathological complex of α -synuclein and TPPP/p25. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2015, 1852, 2653-2661.	1.8	18
14	Modeling of sensing potency of cytoskeletal systems decorated with metabolic enzymes. <i>Journal of Theoretical Biology</i> , 2015, 365, 190-196.	0.8	4
15	Identification of motives mediating alternative functions of the neomorphic moonlighting TPPP/p25. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 547-557.	1.8	25
16	Dual life of TPPP/p25 evolved in physiological and pathological conditions. <i>Biochemical Society Transactions</i> , 2014, 42, 1762-1767.	1.6	11
17	Sensor potency of the moonlighting enzyme-decorated cytoskeleton: the cytoskeleton as a metabolic sensor. <i>BMC Biochemistry</i> , 2013, 14, 3.	4.4	28
18	Microtubule assembly-derived by dimerization of TPPP/p25. Evaluation of thermodynamic parameters for multiple equilibrium system from ITC data. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2012, 1820, 785-794.	1.1	12

#	ARTICLE	IF	CITATIONS
19	A new myelin protein, TPPP/p25, reduced in demyelinated lesions is enriched in cerebrospinal fluid of multiple sclerosis. <i>Biochemical and Biophysical Research Communications</i> , 2011, 409, 137-141.	1.0	22
20	Disordered TPPP/p25 binds GTP and displays Mg ²⁺ -dependent GTPase activity. <i>FEBS Letters</i> , 2011, 585, 803-808.	1.3	26
21	Moonlighting proteins in neurological disorders. <i>IUBMB Life</i> , 2011, 63, 453-456.	1.5	18
22	Interactions of Pathological Hallmark Proteins. <i>Journal of Biological Chemistry</i> , 2011, 286, 34088-34100.	1.6	138
23	Tubulin polymerization-promoting protein (TPPP/p25) is critical for oligodendrocyte differentiation. <i>Glia</i> , 2010, 58, 157-168.	2.5	116
24	Tubulin polymerization promoting protein (TPPP/p25) as a marker for oligodendroglial changes in multiple sclerosis. <i>Glia</i> , 2010, 58, 1847-1857.	2.5	61
25	TPPP/p25 Promotes Tubulin Acetylation by Inhibiting Histone Deacetylase 6. <i>Journal of Biological Chemistry</i> , 2010, 285, 17896-17906.	1.6	91
26	TPPP orthologs are ciliary proteins. <i>FEBS Letters</i> , 2008, 582, 3757-3764.	1.3	31
27	Phosphorylation Blocks the Activity of Tubulin Polymerization-promoting Protein (TPPP). <i>Journal of Biological Chemistry</i> , 2007, 282, 29531-29539.	1.6	58
28	TPPP/p25 in brain tumours: expression in non-neoplastic oligodendrocytes but not in oligodendroglioma cells. <i>Acta Neuropathologica</i> , 2007, 113, 213-215.	3.9	28
29	Tubulin Polymerization Promoting Proteins (TPPPs): Members of a New Family with Distinct Structures and Functions. <i>Biochemistry</i> , 2006, 45, 13818-13826.	1.2	83
30	Dynamic targeting of microtubules by TPPP/p25 affects cell survival. <i>Journal of Cell Science</i> , 2004, 117, 6249-6259.	1.2	69
31	Natively unfolded tubulin polymerization promoting protein TPPP/p25 is a common marker of alpha-synucleinopathies. <i>Neurobiology of Disease</i> , 2004, 17, 155-162.	2.1	140
32	Brain-Specific p25 Protein Binds to Tubulin and Microtubules and Induces Aberrant Microtubule Assemblies at Substoichiometric Concentrations. <i>Biochemistry</i> , 2002, 41, 8657-8664.	1.2	121
33	A Potential Innovative Therapy for Parkinson's Disease: Selective Destruction of the Pathological Assemblies of Alpha-Synuclein. , 0, , .		3